Subcutaneous seeding of hepatocellular carcinoma after percutaneous needle biopsy

Background—In patients with a hepatic mass, malignancy can be diagnosed or excluded by a needle biopsy. However, this procedure can cause the formation of subcutaneous metastatic nodules in the needle tract. We present a case of recurrent subcutaneous seeding four years after a biopsy of a small hepatocellular carcinoma (HCC).

Case report—A 30 year old woman with hepatitis B liver cirrhosis presented with a raised serum alpha-fetoprotein (AFP) (271 µg/l; normal: <20 µg/l); ultrasound detected a liver mass. Additional spiral computed tomography showed a 2 cm diameter subcapsular mass in segment V. There were also two satellite lesions, measuring less than 1 cm in the same segment. To confirm the diagnosis of HCC, an ultrasound guided needle biopsy was performed using an 18 gauge Tru-cut needle and Bioptry-gun. Two passes were needed to obtain adequate specimens. Subsequent histological examination showed HCC. A right hemihepatectomy was performed, resulting in a radically resected multifocal HCC without vascular ingrowth; the main nodule was located subcapsularly. Follow up consisted of ultrasonography and measurement of serum AFP concentrations twice yearly.

After four years, the patient presented with raised serum AFP and a nodule measuring 1 cm diameter in the subcutaneous fat; this was shown by magnetic resonance imaging (fig 1). No hepatic lesions were detected on the liver. An aspiration biopsy showed characteristics of HCC, and the nodule was excised; histological examination revealed a moderately differentiated HCC.

Discussion—Needle biopsies, especially fine needle biopsies, are considered to be relatively safe and accurate in obtaining a diagnosis of malignancy. However, depending on the retrieval rate, the number of passes needed to obtain sufficient material for histological examination varies. In a porcine model, larger (<20 gauge) needles were more efficient as fewer passes were needed to obtain enough material for histological examination. Sangalli and colleagues found a 86.6% retrieval rate suitable for histological examination, but d’Aquino and coworkers found only 10 of 27 samples from cirrhotic livers appropriate.

The incidence of needle track seeding may rise as a result of the puncture of tumours detected at an early stage in patients with a longer life expectancy. A multicentre questionnaire detected a needle track dissemination risk of

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex/age</th>
<th>Treatment</th>
<th>Death after diagnosis</th>
<th>Recurrence site</th>
<th>Diameter of primary tumour</th>
<th>Needle size</th>
<th>Time between FNAB and recurrence</th>
<th>Puncture purpose</th>
<th>Puncture frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nakamuta and colleagues</td>
<td>F/63</td>
<td>PEIT</td>
<td>–</td>
<td>Subcutis</td>
<td>2 cm</td>
<td>21 G</td>
<td>5 months</td>
<td>Diagnostic</td>
<td>–</td>
</tr>
<tr>
<td>Cedrone and colleagues</td>
<td>M/64</td>
<td>PEIT</td>
<td>19 months</td>
<td>Abdominal wall</td>
<td>3.2 cm</td>
<td>20–22 G</td>
<td>6 months</td>
<td>Diagnostic/therapeutic</td>
<td>10</td>
</tr>
<tr>
<td>Evans and colleagues</td>
<td>M/70</td>
<td>Resection</td>
<td>–</td>
<td>Whole needle track</td>
<td>–</td>
<td>–</td>
<td>12 months</td>
<td>Diagnostic</td>
<td>–</td>
</tr>
<tr>
<td>Quaghebeur and colleagues</td>
<td>M/64</td>
<td>Hemihepatectomy</td>
<td>Inoperable because of recurrence</td>
<td>Subcutis</td>
<td>9 cm</td>
<td>Tru-cut?</td>
<td>3 weeks</td>
<td>Diagnostic</td>
<td>–</td>
</tr>
<tr>
<td>John and colleagues</td>
<td>M/71</td>
<td>Hemihepatectomy</td>
<td>Inoperable because of recurrence</td>
<td>Abdominal muscle</td>
<td>10 cm</td>
<td>18 G</td>
<td>2 months</td>
<td>Diagnostic</td>
<td>2</td>
</tr>
<tr>
<td>Park and colleagues</td>
<td>M/67</td>
<td>TCE</td>
<td>–</td>
<td>Subcutis abdominal wall</td>
<td>9 cm</td>
<td>20 G</td>
<td>4 months</td>
<td>Diagnostic</td>
<td>–</td>
</tr>
<tr>
<td>Ondera and colleagues</td>
<td>F/38</td>
<td>TAE</td>
<td>–</td>
<td>Subcutis abdominal wall</td>
<td>4 cm</td>
<td>22 G</td>
<td>3 months</td>
<td>Diagnostic</td>
<td>1</td>
</tr>
<tr>
<td>Sakurai and colleagues</td>
<td>M/62</td>
<td>TCE/TAE/lobectomy</td>
<td>–</td>
<td>Subcutis abdominal wall</td>
<td>4.3 cm</td>
<td>Tru-cut?</td>
<td>8 months</td>
<td>Diagnostic</td>
<td>–</td>
</tr>
<tr>
<td>Yamada and colleagues</td>
<td>F/74</td>
<td>Segmentectomy</td>
<td>–</td>
<td>Subcutis</td>
<td>1.5 cm</td>
<td>21 G</td>
<td>13 months</td>
<td>Diagnostic</td>
<td>2</td>
</tr>
<tr>
<td>Isobe and colleagues</td>
<td>F/47</td>
<td>Left hemihepatectomy</td>
<td>9 months</td>
<td>Subcutis</td>
<td>–</td>
<td>22 G</td>
<td>9 months</td>
<td>Diagnostic</td>
<td>2</td>
</tr>
<tr>
<td>Hezrunz and colleagues</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Subcutis</td>
<td>–</td>
<td>20 G</td>
<td>–</td>
<td>Diagnostic</td>
<td>1</td>
</tr>
<tr>
<td>Jourdan and colleagues</td>
<td>M/34</td>
<td>Left hemihepatectomy</td>
<td>3 years</td>
<td>Intrahepatic</td>
<td>5 cm</td>
<td>&gt;20 G</td>
<td>6 months</td>
<td>Diagnostic</td>
<td>2</td>
</tr>
<tr>
<td>Andersson and colleagues</td>
<td>M/62</td>
<td>Hemihepatectomy</td>
<td>Inoperable</td>
<td>Subcutis, needle track</td>
<td>–</td>
<td>–</td>
<td>1 month</td>
<td>Diagnostic</td>
<td>–</td>
</tr>
<tr>
<td>Current study</td>
<td>F/36</td>
<td>Hemihepatectomy</td>
<td>–</td>
<td>Abdominal wall</td>
<td>2 cm</td>
<td>18 G</td>
<td>4 years</td>
<td>Diagnostic</td>
<td>–</td>
</tr>
</tbody>
</table>

PEIT, percutaneous ethanol injection therapy; TCE, transcatheter embolisation; TAE, transarterial embolisation; G, gauge.
Correspondence to: Dr IJzermans (email: IJzermans@hlkd.azr.nl).

0.006%, consistent with the risk found in other studies. In an animal model, 106 to 107 tumour cells could be seeded from a solid tumour by a fine needle biopsy5; tumour growth resulted in 85% of these seedings. Andersson et al concluded that the incidence of implantation metastases after fine needle procedures is probably underestimated because the number of reported cases is not consistent with estimated recurrence risks and, in some cases, recurrence was not reported although known to exist.10 To our knowledge, 15 needle track seedings after biopsy of HCC have been reported during the past 15 years (table 1).11 In most of these cases, diagnosis of HCC was followed by curative treatment (n=7). Two patients had irresectable cancer because of needle track recurrence, and the primary tumour could not be resected in a further two patients.

**Conclusion**—A critical evaluation of the role of needle biopsies in resectable HCC is needed. A needle biopsy may be indicated only if it is not possible to diagnose HCC by other means—such as increased AFP concentrations, spiral computed tomography, or magnetic resonance imaging. The needle track should be marked on the skin and pass through liver tissue. Finally, the entire track should be resected at surgery for the primary tumour. A single pass with a larger needle (18 gauge) may be preferable to multiple passes with smaller calibre needles. Needle biopsies are not indicated to confirm HCC in patients suitable for liver transplantation.

S N SCHOTMAN

Departments of General Surgery

R A DE MAN

Department of Hepatogastroenterology

J STOKER

Department of Radiology

P E ZONDERVAN

Department of Pathology

J N M IJZERMANS

Department of General Surgery,

Erasmus University Hospital Dijkzigt,

PO Box 2040, 3000 CA Rotterdam,

The Netherlands


Subcutaneous seeding of hepatocellular carcinoma after percutaneous needle biopsy

S N SCHOTMAN, R A DE MAN, J STOKER, P E ZONDERVAN and J N M IJZERMANS

Gut 1999 45: 626-627
doi: 10.1136/gut.45.4.626

Updated information and services can be found at:
http://gut.bmj.com/content/45/4/626

These include:

References
This article cites 23 articles, 1 of which you can access for free at:
http://gut.bmj.com/content/45/4/626#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Hepatic cancer (474)
Cirrhosis (331)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/